

340B Distribution Practice Fact Sheet

In November 2019, Bristol Myers Squibb (BMS) acquired Celgene Corporation. Since that time, BMS has made progress integrating our complex business operations consistent with our vision of transforming patients' lives. As part of our integration efforts, BMS has developed a coordinated, enterprise-wide approach to the company's distribution practices. Our new 340B distribution practice reflects this broader integration and alignment of our distribution model, exempts grantees, and offers stakeholders the opportunity to collaborate further on pro-patient solutions. BMS is committed to ensuring eligible 340B patients directly benefit from the program, and that patients maintain access to our medicines.

Questions regarding these integration changes may be submitted to BMS340B@bms.com.

Contract Pharmacy Practice
Beginning March 1, 2022, BMS will recognize up to two designated 340B contract pharmacy locations per 340B hospital that lacks an entity-owned pharmacy: one for Revlimid®, Pomalyst®, Thalomid® (IMiDs), and a second for non-IMiD products.
<ul style="list-style-type: none"> • 340B covered entities that are not already part of the IMiD limited distribution network will have the option to access 340B prices on the IMiDs through one in-network IMiD-designated specialty contract pharmacy location per covered entity. <ul style="list-style-type: none"> ○ AmerisourceBergen Corporation is the exclusive distributor for IMiD out-of-network covered entities' IMiD contract pharmacy orders. ○ Entities choosing this option submit information to BMS directly, which ensures: <ul style="list-style-type: none"> ▪ Prescription fill dates occurred after March 1, 2022 ▪ Multiple 340B requests are not claimed on a single eligible prescription.
<ul style="list-style-type: none"> • (Updated May 2022) 340B covered entities that are not already part of the CAMZYOS limited distribution network will have the option to access the product at a 340B price through one in-network CAMZYOS designated specialty contract dispensing pharmacy location per covered entity.
Exemptions
<ul style="list-style-type: none"> • All grantee covered entity types will be allowed to access 340B prices for multiple contract pharmacy locations for non-IMiDs. • For hospitals, one contract pharmacy location is permitted for non-IMiDs if the entity doesn't have an entity-owned pharmacy. • 340B hospitals will be eligible to designate wholly owned pharmacies as contract pharmacy locations.
Collaboration
<ul style="list-style-type: none"> • BMS considers the 340B program to be a critical part of America's health care safety net. BMS also recognizes, however, that the program is evolving and has become increasingly complex for stakeholders to navigate. • BMS invites stakeholders to partner with BMS to consider and test potential solutions to the challenges that face 340B. • Such models may include extending 340B pricing directly to uninsured and vulnerable patients at the point of sale, sharing data to prevent diversion and duplicate discounts, or exploring third party contract pharmacy models that align with state and federal law. • Stakeholders interested in partnering with BMS may submit ideas to 340BCollaborative@bms.com.

Any patient having issues obtaining or affording a BMS medicine should visit our patient support website at: <https://www.bms.com/patient-and-caregivers/get-help-paying-for-your-medicines.html>